Some WHO-approved malaria drugs fall short: study

Up to eight percent of malaria drugs approved by the World Health Organization or other regulators do not contain the right dose and may fuel resistance, researchers said Tuesday.

Two studies in published in Research and Reports in suggested manufacturing problems, rather than counterfeiting, may be to blame for these substandard drugs in low and around the world.

Poorly made or fake medications are a major problem worldwide, particularly as signs emerge of growing resistance to artemisinin, the frontline treatment for malaria, a disease the UN's (WHO) says killed 655,000 people in 2010.

One study sampled 104 artemisinin-based medicines from pharmacies in Ghana and Nigeria that were offered under the Affordable Medicines Facility by the Global Fund to Fight AIDS, designed to boost access to the best treatments.

Eight were found to be significantly under-dosed in artemisinin, or had less than 75 percent of the main component of the drug, the study authors said.

"Why am I pretty sure that these are not fakes?" asked Roger Bate, lead author and resident scholar at the American Enterprise Institute.

"The reason is they have well over 50 percent of the active ingredient but under 75 percent," he said, adding that most counterfeits have very little or no in them.

A separate study that spanned 2,652 essential drugs -- including medicines for malaria, tuberculosis and bacterial infections -- found that the failure rate among WHO-approved products was 6.8 percent.

The samples came from 11 sites in Africa, three Indian cities, as well as Sao Paulo, Moscow, Bangkok, Istanbul and Beijing.

The highest failure rate -- 17.65 percent -- was seen among Chinese-made products approved by the WHO, said the study.

Researchers said the WHO has launched an investigation.

add to favorites email to friend print save as pdf

Related Stories

Fake malaria drugs a growing problem: experts

Dec 05, 2011

Fake or poor quality malaria drugs are boosting resistance in parts of southeast Asia, a problem that is likely to worsen unless tighter regulations are adopted, US experts said Monday.

Bad malaria pills in Africa raise resistance fears

Feb 08, 2010

(AP) -- High rates of the most effective type of malaria-fighting drugs sold in three African countries are poor quality - including nearly half the pills sampled in Senegal - raising fears of increased drug resistance that ...

Fake malaria drugs threaten crisis in Africa

Jan 17, 2012

(Medical Xpress) -- The emergence of fake and poor quality anti-malarial drugs could dash hopes of controlling malaria in Africa, warn experts writing in the Malaria Journal. Millions of lives could be put ...

WHO hopeful drug-resistant malaria can be contained

Apr 24, 2012

The World Health Organisation said Tuesday it was optimistic drug-resistant malaria that has emerged along Thailand's borders with Cambodia and Myanmar could be contained within the region.

Recommended for you

Determine patient preferences by means of conjoint analysis

5 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments